Please use this identifier to cite or link to this item:
|Title:||An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography|
|Authors:||Wang, L.-Z. |
|Source:||Wang, L.-Z., Goh, B.-C., Lee, H.-S., Noordhuis, P., Peters, G.J. (2003-10). An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography. Therapeutic Drug Monitoring 25 (5) : 552-557. ScholarBank@NUS Repository. https://doi.org/10.1097/00007691-200310000-00003|
|Abstract:||An expedient method is presented for determination in human plasma of gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine (dFdU) by ion-pair reversed-phase HPLC. Samples were simply prepared by protein precipitation. Separation was processed on a Thermo Hypersil column (250 × 4.6 mm, 5 μm Hypersil® BDS C18) with UV detection at 272 nm. The mobile phase consisted of 17% methanol and 83% phosphate buffer (20 mM, pH 3.1) containing 10 mM sodium 1-heptanesulfonate with a flow rate of 0.8 mL/min. The lower limit of quantification (LLOQ) of gemcitabine was 0.08 μg/mL with linear response over the range 0.08-20.0 μg/mL, and LLOQ of dFdU was 0.1 μg/mL with linear response over the range 0.1-50.0 μg/mL. Assay accuracy for both compounds was within ± 4%. The coefficient of variation (CV %) for intra- and interday precision for both compounds was|
|Source Title:||Therapeutic Drug Monitoring|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 21, 2018
WEB OF SCIENCETM
checked on Jan 16, 2018
checked on Feb 18, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.